Home・Elenco Azioni・Allogene Therapeutics Inc

Allogene Therapeutics Inc

Chiusa

SettoreSettore sanitario

2 2.04

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.95

Massimo

2.02

Metriche Chiave
By Trading Economics
Entrata	-3.8M -43M
EPS	-0.18
Dipendenti	150
EBITDA	-91K -39M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+407.61% upside

Dividendi
By Acuity
Utili prossimi	12 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-152M 635M
Apertura precedente	-0.04
Chiusura precedente	2

Allogene Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

7 ago 2026, 19:16 UTC

Correlated Moves

Biotechnology stocks are rising, boosting Allogene Therapeutics shares. The ARK Genomic Revolution ETF has also increased, reflecting positive sector momentum.

6 ago 2026, 19:46 UTC

Correlated Moves

Allogene Therapeutics shares are lower, reflecting broader market trends, as the Russell 2000 Index also declined during Thursday's session.

5 ago 2026, 22:01 UTC

Allogene Therapeutics Inc shares are lower in after-market trading, reflecting a pullback from earlier gains amid broader market volatility following weaker U.S. job growth data.

3 ago 2026, 20:06 UTC

Allogene Therapeutics Inc. shares are trading lower, continuing a decline since Friday's close, despite broader market gains in the S&P 500 and Nasdaq 100.

30 lug 2026, 20:04 UTC

Correlated Moves

Event

Allogene Therapeutics receives RMAT and Fast Track designations from the FDA for cema-cel, contributing to gains in shares today.

29 lug 2026, 23:51 UTC

Event

Correlated Moves

Allogene Therapeutics receives FDA RMAT and Fast Track designations for cema-cel, boosting shares higher in after-market hours. The Russell 2000 Index's rise may also contribute.

28 lug 2026, 20:02 UTC

Allogene Therapeutics Inc shares are lower amid negative market sentiment following a significant sell-off in technology stocks across Asian markets.

27 lug 2026, 18:07 UTC

Allogene Therapeutics Inc shares are higher today, despite earlier fluctuations. The market backdrop features a decline in oil prices, easing inflation concerns.

24 lug 2026, 19:46 UTC

Correlated Moves

Allogene Therapeutics Inc is lower today amid broader market declines, with the Russell 2000 Index down and oil price volatility impacting the biotechnology sector.

23 lug 2026, 22:56 UTC

Allogene Therapeutics Inc. shares are roughly flat in after-market trading, remaining below their 20-day moving average and near the lower end of their one-month range.

22 lug 2026, 20:13 UTC

Correlated Moves

Allogene Therapeutics Inc shares are lower in after-market trading, reflecting broader market declines amid rising crude oil prices and geopolitical tensions.

21 lug 2026, 18:46 UTC

Correlated Moves

Social Media

Allogene Therapeutics shares are higher following positive TRAVERSE trial results for ALLO-316, which showed a 25% overall response rate in patients.

20 lug 2026, 23:26 UTC

Allogene Therapeutics Inc. shares are higher in after-market trading, with no specific news identified. Broader market volatility continues to influence investor sentiment.

Confronto tra pari

Modifica del prezzo

Allogene Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

407.61% in crescita

Previsioni per 12 mesi

Media 10 USD 407.61%

Alto 14 USD

Basso 7 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Allogene Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

6 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 6 che hanno fornito valutazioni azionarie a Allogene Therapeutics Inc - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.